Received Jul 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | LA |
Rash around injection site, flushing and itchiness.; flushing; itchiness; This non-serious case was reported by a other health professional via sales rep and described the occurrence of injection site rash in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 18-JUN-2025, the patient received the 1st dose of Shingrix (left deltoid). On 20-JUN-2025, 2 days after receiving Shingrix, the patient experienced injection site rash (Verbatim: Rash around injection site, flushing and itchiness.), flushing (Verbatim: flushing) and pruritus (Verbatim: itchiness). The outcome of the injection site rash, flushing and pruritus were not resolved. The reporter considered the injection site rash, flushing and pruritus to be related to Shingrix. The company considered the injection site rash, flushing and pruritus to be related to Shingrix. Additional Information: GSK Receipt Date: 26-JUN-2025 The Medical assistant reported that a female patient received the first dose of Shingrix vaccine and experienced rash around injection site, flushing and itchiness